Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
(Thomson Reuters ONE) - Addex Pharmaceuticals / Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Geneva, Switzerland, 8 February 2010 - Addex Pharmaceuticals (SIX:ADXN), theallosteric modulation company, announced today that ADX71943 has demonstratedstatistically significant analgesic-like effects in three preclinical models ofpain.In the first model, ADX71943 reversed complete Freund adjuvant (CFA)-inducedreductions in withdrawal thresholds in a dose-related manner, with a minimumstatistically significant effective oral dose of 10 mg/kg. In a second model(Formalin test), ADX71943 showed anti-nociceptive effect after oraladministration of 3 to 10 mg/kg. In a third model, an increased visceral painthreshold was seen using ADX71943 with a minimum statistically significanteffective dose between 3 and 10 mg/kg.ADX71943 is an orally available positive allosteric modulator (PAM) of theGABA(B) receptor that has potential for treatment of osteoarthritis pain andchronic nociceptive pain as well as other indications. ADX71943 has a gooddevelopability profile and is expected to enter clinical testing in the fourthquarter 2010."We are impressed with the profile of the compound and by its activity in thesemodels. Furthermore,minimum effective doses observed in the preclinical models and thepharmacokinetic properties of the compound support prediction of treatmentregimens in humans compatible with the target patient population and disease"said Sonia Poli, head of non-clinical development at Addex.GABA(B) activation is a clinically validated mechanism. Baclofen, a GABA(B)agonist, is widely used for its muscle relaxant properties in the control ofspasticity caused by multiple sclerosis, cerebral palsy or certain injuries tothe spine. Furthermore, Baclofen is a powerful analgesic agent, especially whendelivered intrathecally. However, rapid induction of tolerance and dose limitingCNS-mediated side effects (e.g. sedation, hypothermia, memory impairment)prevent baclofen from being widely prescribed for pain relief despite itsanalgesic properties. ADX71943, an allosteric modulator with a differentiatedprofile, could avoid the tolerance and dose limiting side effects commonlyassociated with baclofen.Osteoarthritis (OA) is a widespread condition affecting the elderly populationin particular. One of the most debilitating symptoms is chronic pain associatedwith OA. Patients suffering from chronic pain will require treatment over thelong-term. There is a clear need for drugs with better side effect profiles thancurrent marketed drugs (e.g. non-steroidal anti-inflammatory drugs and opioids).Addex Pharmaceuticals (www.addexpharma.com )utilizes its unique proprietary platform technologies to discover and developallosteric modulators for human health. Allosteric modulators are a differentkind of orally available small molecule therapeutic agent, which we believe willoffer a competitive advantage over classical drugs. With 15 programs indevelopment, the Addex pipeline demonstrates the productivity and broadpotential of our unparalleled platform technologies. The most advanced product,ADX48621, an mGluR5 negative allosteric modulator (NAM), has completed Phase Itesting and is scheduled to start Phase II testing for Parkinson's diseaselevodopa associated dyskinesia (PD-LID) later in 2010.Our products and technology already have proven their value through ourrelationships with four of the top 10 pharmaceutical companies in the world.Specifically, under an agreement withOrtho-McNeil-Janssen Inc., a Johnson &Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), isundergoing Phase I clinical testing and has potential for treatment ofschizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson'sdisease and schizophrenia, respectively. In addition, SR-One, the corporateventure arm of GlaxoSmithKline, and Roche Venture Fund have made equityinvestments in Addex.Chris MaggosInvestor Relations & CommunicationsAddex Pharmaceuticals+41 22 884 15 11chris.maggos(at)addexpharma.com Disclaimer: The foregoing release contains forward-looking statements that canbe identified by terminology such as "not approvable", "continue", "believes","believe", "will", "remained open to exploring", "would", "could", or similarexpressions, or by express or implied discussions regarding AddexPharmaceuticals Ltd, its business, the potential approval of its products byregulatory authorities, or regarding potential future revenues from suchproducts. Such forward-looking statements reflect the current views of AddexPharmaceuticals Ltd regarding future events, and involve known and unknownrisks, uncertainties and other factors that may cause actual results withallosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets tobe materially different from any future results, performance or achievementsexpressed or implied by such statements. There can be no guarantee thatallosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale inany market or by any regulatory authority. Nor can there be any guaranteethat allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutictargets will achieve any particular levels of revenue (if any) in the future. Inparticular, management's expectations regarding allosteric modulators ofmGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, amongother things, unexpected actions by our partners, unexpected regulatory actionsor delays or government regulation generally; unexpected clinical trial results,including unexpected new clinical data and unexpected additional analysis ofexisting clinical data; competition in general; government, industry and generalpublic pricing pressures; the company's ability to obtain or maintain patent orother proprietary intellectual property protection. Should one or more of theserisks or uncertainties materialize, or should underlying assumptions proveincorrect, actual results may vary materially from those anticipated, believed,estimated or expected. Addex Pharmaceuticals is providing the information inthis press release as of this date and does not undertake any obligation toupdate any forward-looking statements contained in this press release as aresult of new information, future events or otherwise.[HUG#1381443] --- End of Message --- Addex Pharmaceuticals12, chemin des Aulx Plan-les-Ouates; Geneva SwitzerlandISIN: CH0029850754; Fran?s (pdf): http://hugin.info/138017/R/1381443/340695.pdf English (pdf): http://hugin.info/138017/R/1381443/340694.pdf Deutsch (pdf): http://hugin.info/138017/R/1381443/340696.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:Leseranfragen:PresseKontakt / Agentur:Bereitgestellt von Benutzer: hugin
Datum: 08.02.2010 - 01:00 Uhr
Sprache: Deutsch
News-ID 1010058
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Anmerkungen:
Diese Pressemitteilung wurde bisher
126 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals
(
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
